ASCI upholds complaints against 232 misleading advertisements

Image
Press Trust of India New Delhi
Last Updated : Nov 28 2017 | 9:55 PM IST
Advertising sector watchdog ASCI upheld complaints against 232 misleading advertisements, including those of Merck, HUL, Dabur, Volkswagen Group Johnson & Johnson, Ambuja Cements, Apollo Hospitals and GCPL, for the month of September.
The Customer Complaints Council (CCC) of Advertising Standards Council of India (ASCI) received 305 complaints in the month.
It upheld 151 complaints in the education category, 62 in the healthcare category, 7 in the Food & Beverages category, 4 in the Personal Care category and three in the personal care category and 8 from others.
ASCI has upheld claim against Volkswagen Group Sales India for its ad claiming low EMI subject to terms and conditions.
However, the ad regulator found that Volkswagen had neither substantiated the basis with calculations for claiming low EMI of Rs 7,999 for Polo version and Rs 11,999 for Vento nor given any evidence of such low EMI being availed by any of their customers.
"Furthermore, the advertisement is misleading by omission of the details regarding the number of months for the EMI payment and the source / web-site details where a customer could look up the EMI calculations," it said.
It has also upheld claims against FMCG major HUL, where it had claimed "Pink Pearls from Korea that gives inner fairness and Japanese Green Tea for pimple clear skin" its Citra range of product.
According to ASCI, the use of the ingredients in question in the product was misleading as the quantity or percentage in the product was not specified.
Similarly, Johnson & Johnson was also pulled up for its ad on Johnson's Baby Laundry Detergent where it's claim of "Best Cleaning" was "inadequately substantiated with comparative data against the competition either in detergent for babycare or in the general detergents category".
Drug firm Merck's claim of "It is time to say goodbye to tiredness and fatigue", "Enhance your life by rejuvenating yourself" and "High on energy, high on life" for its vitamin B-complex Polybion was found "misleading by ambiguity and omission as they do not talk of deficiency state of an individual who would consume this Vitamin supplement."
Apollo Hospitals' claims "Get rid of seizures" and "Let us eliminate Epilepsy" were "considered to be, prima facie, in violation of the D&C Rules (Drugs and Cosmetics)."
Similarly, complaints against Ambuja Cements was upheld for its ad of Ambuja Plus Cool Walls, where it had claimed "Now your city will remain five degrees cooler during summers", "Strong walls made with heat barrier technology, and "Heat resistance concrete blocks".
ASCI had found that claims " were not substantiated with supporting technical data, and are misleading by exaggeration".

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 28 2017 | 9:55 PM IST

Next Story